EVOK Stock Overview
A specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Evoke Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.20 |
| 52 Week High | US$12.32 |
| 52 Week Low | US$3.54 |
| Beta | 0.15 |
| 1 Month Change | 2.44% |
| 3 Month Change | -19.08% |
| 1 Year Change | -53.33% |
| 3 Year Change | -94.27% |
| 5 Year Change | -98.15% |
| Change since IPO | -99.75% |
Recent News & Updates
Recent updates
Evoke Pharma (NASDAQ:EVOK) Is Using Debt Safely
Jan 22
Evoke to get US patent for nasal spray Gimoti
Sep 20Evoke Pharma Q2 GAAP loss per share narrows, revenue up
Aug 10Evoke Pharma gets Canadian patent linked to Gimoti nasal spray
Jul 06Does Evoke Pharma (NASDAQ:EVOK) Have A Healthy Balance Sheet?
Oct 22Does Evoke Pharma (NASDAQ:EVOK) Have A Healthy Balance Sheet?
Jul 06Evoke Pharma announces positive findings from second GIMOTI market research study
Jun 15Evoke Pharma pops 8% after Gimoti listed in FDA Orange Book
Jun 08Evoke Pharma issued new U.S. patent covering methods of use for Gimoti
Jun 02Evoke Pharma, Inc.'s (NASDAQ:EVOK) Shift From Loss To Profit
Mar 14Shareholder Returns
| EVOK | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -9.5% | 0.2% | -0.5% |
| 1Y | -53.3% | 2.0% | 23.2% |
Return vs Industry: EVOK underperformed the US Pharmaceuticals industry which returned 2% over the past year.
Return vs Market: EVOK underperformed the US Market which returned 23.2% over the past year.
Price Volatility
| EVOK volatility | |
|---|---|
| EVOK Average Weekly Movement | 15.2% |
| Pharmaceuticals Industry Average Movement | 10.9% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.6% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: EVOK's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: EVOK's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 4 | Matt D'Onofrio | www.evokepharma.com |
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers.
Evoke Pharma, Inc. Fundamentals Summary
| EVOK fundamental statistics | |
|---|---|
| Market cap | US$9.11m |
| Earnings (TTM) | -US$6.15m |
| Revenue (TTM) | US$8.62m |
1.0x
P/S Ratio-1.4x
P/E RatioIs EVOK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EVOK income statement (TTM) | |
|---|---|
| Revenue | US$8.62m |
| Cost of Revenue | US$297.06k |
| Gross Profit | US$8.32m |
| Other Expenses | US$14.47m |
| Earnings | -US$6.15m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.97 |
| Gross Margin | 96.55% |
| Net Profit Margin | -71.33% |
| Debt/Equity Ratio | 114.0% |
How did EVOK perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 23:32 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Evoke Pharma, Inc. is covered by 12 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raghuram Selvaraju | Aegis Capital Corporation |
| Edward Woo | Ascendiant Capital Markets LLC |
| Difei Yang | Brean Capital |